Caption Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Caption Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-35,000	Closed	-$7.59M	–	1625
2023 Q2	$7.59M	Buy	35,000 +15,000	+75%	+$3.21M	0.13%	193
2023 Q1	$3.63M	Buy	20,000 +5,000	+33%	+$956K	0.07%	303
2022 Q4	$2.95M	Hold	15,000	–	–	0.05%	455
2022 Q3	$3.37M	Hold	15,000	–	–	0.05%	474
2022 Q2	$1.9M	Buy	+15,000	New	+$1.72M	0.03%	684
2021 Q4	–	Sell	-6,400	Closed	-$783K	–	2027
2021 Q3	$783K	Buy	+6,400	New	+$739K	0.01%	1096

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Caption Management's KRTX Position: Q4 2023 in Review

Caption Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2023, closing a stake of 7,900 shares — an estimated $1.54M sold.

Caption Management first reported a position in KRTX in Q3 2021 and held it in 4 quarters. The position peaked at $1.34M in Q3 2023. 328 funds tracked by Wall St. Rank hold KRTX as of Q4 2023.

Caption Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Caption Management sold 7,900 Karuna Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $1.54M.
Caption Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
Caption Management's Karuna Therapeutics, Inc. Common Stock position peaked at $1.34M in Q3 2023.
328 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Caption Management's 13F filing for Q4 2023, filed 14 Feb 2024.